Crohn's Disease

Cardiometabolic and Mortality Risks in Chronic Inflammatory Disorders

Cardiometabolic and Mortality Risks in Chronic Inflammatory Disorders

Certain inflammatory disorders may increase the risk for cardiometabolic events and all-cause mortality.

Remicade Biosimilar FDA-Approved

Remicade Biosimilar FDA-Approved

By

The FDA has approved Renflexis, the second approved biosimilar to Remicade.

Sign Up for Free e-Newsletters